Enanta Pharmaceuticals to Present at Upcoming Investor Conference

WATERTOWN, Mass.–(BUSINESS WIRE)–Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and
development-focused biotechnology company dedicated to creating small
molecule drugs for viral infections and liver diseases, today announced
that Jay R. Luly, Ph.D., President and Chief Executive Officer, will
participate in a fireside chat presentation format at the following
investor conference:

May 22, 1:35 p.m. ET; 2019 RBC Capital Markets Global Healthcare
Conference, New York City.

A live webcast of the presentation will be accessible by visiting the
“Events and Presentations” section on the “Investors” page of Enanta’s
website at www.enanta.com.
A replay of the webcast will be available following the presentation and
will be archived for approximately 30 days.

About Enanta
Enanta Pharmaceuticals is using its robust,
chemistry-driven approach and drug discovery capabilities to become a
leader in the discovery and development of small molecule drugs for the
treatment of viral infections and liver diseases. Enanta’s research and
development efforts are currently focused on the following disease
targets: respiratory syncytial virus (RSV), non-alcoholic
steatohepatitis (NASH)/ primary biliary cholangitis (PBC), and hepatitis
B virus (HBV).

Enanta’s research and development activities are funded by royalties
from HCV products developed under its collaboration with AbbVie.
Glecaprevir, a protease inhibitor discovered by Enanta, is now sold by
AbbVie in numerous countries as part of its newest treatment for chronic
hepatitis C virus (HCV) infection. This leading HCV regimen is sold
under the tradenames MAVYRET™ (U.S.) and MAVIRET™ (ex-U.S.)
(glecaprevir/pibrentasvir). Please visit www.enanta.com
for more information.

Contacts

Investor Contact
Carol Miceli
617-607-0710
[email protected]